1. David M. Lubaroff, PhD Founder and Chief Scientific Officer
OHANA VACCINES, LLC
Partnering for Growth March 2018
David M. Lubaroff, PhD Founder and Chief Scientific Officer
Ohana Vaccines, LLC

2. The Problem: Prostate Cancer is a Killer
1,110,000
Globally there are 1.11 M new cases and 307,000 deaths.
In 2018, 164,690 men in the US will be diagnosed with prostate cancer and greater than 29,000 will die.
164,690
~ 30%
After initial treatment, about 20-30% of men will show signs of cancer recurrence.
There is no cure for recurrent prostate cancer
Ohana Vaccines, LLC

3. Immunotherapy is the New Solution
Treatments
Immunotherapy is the New Solution
Immunotherapies only destroy tumor cells and have no effect on normal cells.
Current treatments for recurrent prostate cancer may extend survival, but eventually the cancer continues to grow, resulting in death.
All of the treatments are accompanied by significant side effects, reducing the patient’s quality of life.
Ohana Vaccines, LLC

4. How Does Ohana Vaccines, LLC Contribute to the Solution?
Use a proprietary & unique combination of safe, non-replicating virus vaccines to target antigens associated with prostate cancer.
The “prime-boost” strategy caused the destruction of established prostate cancers in pre-clinical studies.
Produce & test vaccines that target multiple prostate cancer-associated antigens
Use combinations of vaccine immunotherapy with checkpoint inhibitors.
Ohana Vaccines, LLC

5. Anti-Prostate Cancer Vaccines
What Does Ohana Vaccines, LLC do? A pharmaceutical company that develops…
Anti-Prostate Cancer Vaccines
‘Off-the-Shelf’
Therapeutic Vaccines
Cure or extend life greater than currently observed, all without serious side effects
Ohana Vaccines, LLC

6. Immunotherapeutic Vaccines by Ohana Vaccines. LLC
Ohana aims to cure recurrent prostate cancer -
without significant side effects.
Ohana employs a “prime-boost” strategy with proven efficiency in preclinical studies.
The priming vaccine has been tested in preclinical and clinical studies.
Ohana Vaccines, LLC

7. Market Opportunity of Recurrent Prostate Cancer
Total cost $175B for cancer treatment in 2020
Prostate cancer/ all cancer
10.7% prostate cancer in the US
Target: recurrent prostate cancer In the US
20-30 % recurrence
Market : Global $175 B
US Market : $18.7 B
Target :
up to $5.62 B
Hospitalizations alone were estimated to cost $1.9 B in the US and $13.64 B globally.
Future Oncol, 2015; 11 (3):
Ohana Vaccines, LLC

8. Ohana Vaccines, LLC Milestones
FDA Open to Single Pivotal Combined Phase I/II Trial
(2018)
Raising Seed Capital to complete Phase I/II Trial
Additional Clinical Trials and/or Exit
(2019)
Phase I & II Trials for both adenovirus and Phase I for alphavirus vaccines completed successfully
A Provisional Patent application was submitted on April 19, 2017
Ohana Vaccines, LLC

9. Ohana Vaccines, LLC Generates Promising Results in Fighting Prostate Cancer
Both vaccines that will be used in the Prime-Boost protocol were safe in the previous Phase I and Phase II clinical studies
Ohana vaccines priming vaccine caused the induction of immune responses and clinical benefits
In the new preclinical studies, the booster vaccine demonstrated the ability to induce antigen-specific immune responses
Ohana’s Prime-Boost protocol induced the highest level of anti-PSA immune responses and destroyed established tumors in 100% of the vaccinated mice.
Ohana Vaccines, LLC

10. The Company Management Team: Hank Harris, DVM, PhD - CEO
Matthew Lubaroff MBA - COO
David M Lubaroff, PhD - Founder & CSO
Mark Ehrmann, JD, - legal and patents
Advisory Board:
George Weiner, MD
Gail Bishop, PhD
Wendy Maury, PhD
Joel Harris, BA
Adam Koppes, JD
Mark Ehrmann, JD

11. Thank You
Questions?